Literature DB >> 15662602

The surgical management of muscle invasive bladder cancer: a contemporary review.

Michael S Cookson1.   

Abstract

Muscle-invasive bladder cancer is a potentially lethal disease with a high rate of cure if timely and effective therapy is applied while the disease is confined to the bladder or regional lymph nodes. Radical cystectomy is the gold standard to which all other local therapies including multimodality bladder-preserving strategies should be compared. Contemporary cystectomy combined with regional lymphadectomy may be performed with an acceptably low morbidity, provides unparalleled local control, and may result in durable disease-free survival even among patients with locoregional lymph node metastases. Refinements in surgical technique coupled with the expanded application of continent urinary diversion have resulted in excellent functional outcomes without compromising cancer control in properly selected patients. An increasing awareness of the importance of quality-of-life issues combined with an enhanced understanding of tumor biology have resulted in the surgical modifications which include an expanded role for lymphadectomy and preservation of uninvolved adjacent organs.

Entities:  

Mesh:

Year:  2005        PMID: 15662602     DOI: 10.1016/j.semradonc.2004.07.009

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  12 in total

1.  Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.

Authors:  Yang Yan; Feng-Qiang Yang; Hai-Min Zhang; Jun Li; Wei Li; Guang-Chun Wang; Jian-Ping Che; Jun-Hua Zheng; Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience.

Authors:  Gurdarshan S Sandhu; Armen Aprikian; Joseph Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Wassim Kassouf; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

Review 3.  Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review.

Authors:  Georgios Koukourakis; Vassilios Kouloulias; Georgios Zacharias; Anastasia Sotiropoulou-Lontou; Michael Koukourakis
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

4.  Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.

Authors:  Jialiang Zhu; Ziwen Lu; Mang Ke; Xianguo Cai
Journal:  Int Urol Nephrol       Date:  2022-04-25       Impact factor: 2.370

5.  Efficacy of bladder-preserving therapy for patients with t3b, t4a, and t4b transitional cell carcinoma of the bladder.

Authors:  Jaewoo Cheon; Hyunchul Chung; Jaemann Song
Journal:  Korean J Urol       Date:  2010-08-18

6.  The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway.

Authors:  Yihong Zhou; Xi Chu; Fei Deng; Liang Tong; Guoxiong Tong; Ye Yi; Jianye Liu; Jin Tang; Yuxin Tang; Yang Xia; Yingbo Dai
Journal:  Oncotarget       Date:  2017-07-25

7.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

8.  High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy.

Authors:  Jianye Liu; Yonghong Li; Yiji Liao; Shijuan Mai; Zhiling Zhang; Zhouwei Liu; Lijuan Jiang; Yixin Zeng; Fangjian Zhou; Dan Xie
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411

9.  PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.

Authors:  Jian-Ye Liu; Dong Qian; Li-Ru He; Yong-Hong Li; Yi-Ji Liao; Shi-Juan Mai; Xiao-Peng Tian; Yan-Hui Liu; Jia-Xing Zhang; Hsiang-Fu Kung; Yi-Xin Zeng; Fang-Jian Zhou; Dan Xie
Journal:  Mol Cancer       Date:  2013-11-23       Impact factor: 27.401

10.  METTL13 is downregulated in bladder carcinoma and suppresses cell proliferation, migration and invasion.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong; Bo Zhan; Xiao Dong; Xiaojun Man
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.